Related Experiment Video
Updated: Feb 15, 2026

One Dimensional Turing-Like Handshake Test for Motor Intelligence
Published on: December 15, 2010
TFIID and MYB Share a Therapeutic Handshake in AML
Charles C Bell1, Mark A Dawson2
1Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC 3052, Australia.
Abstract:
Selectively disrupting oncogenic transcription factors in cancer remains an elusive ambition of targeted therapeutics. In this issue of Cancer Cell, Xu et al. provide an elegant proof-of-concept study demonstrating that interaction between MYB and the general transcriptional coactivator TFIID can be specifically disrupted to mediate a therapeutic effect in AML.
Insights
Targeting cancer-driving transcription factors is difficult. This study shows disrupting the MYB-TFIID interaction offers a new therapeutic strategy for acute myeloid leukemia (AML).
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Targeted cancer therapies aim to disrupt specific oncogenic drivers.
- Selectively inhibiting transcription factors has been a significant challenge in drug development.
- Acute myeloid leukemia (AML) often involves dysregulated transcription factors.
Purpose of the Study:
- To demonstrate a proof-of-concept for disrupting the interaction between MYB and TFIID.
- To explore this disruption as a potential therapeutic strategy for AML.
Main Methods:
- Investigated the interaction between the MYB transcription factor and the general transcriptional coactivator TFIID.
- Developed and tested a method to specifically disrupt this interaction.
Main Results:
- Successfully demonstrated that the MYB-TFIID interaction can be specifically disrupted.
- Showcased the therapeutic potential of this disruption in AML models.
Conclusions:
- Disrupting the MYB-TFIID interaction is a viable strategy for targeting oncogenic transcription factors.
- This approach offers a novel therapeutic avenue for AML treatment.
More Related Videos
04:24Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
Published on: June 16, 2023
08:32Neurovascular Network Explorer 2.0: A Simple Tool for Exploring and Sharing a Database of Optogenetically-evoked Vasomotion in Mouse Cortex In Vivo
Published on: May 4, 2018
Related Concept Videos
Techniques of therapeutic communication I: Active Listening, Sharing Observations, Validation, and Using Touch
Therapeutic communication is not the same as social interaction. Social interaction has no goal or purpose and consists of casual information sharing, whereas therapeutic communication has a plan or purpose for the conversation. Therapeutic...
Therapeutic Index
Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Microorganisms in Medicine and Therapeutics
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...